Welcome to our dedicated page for Lifeward SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Weight-support algorithms, FDA device clearances, and reimbursement footnotes can turn Lifeward Ltd’s disclosures into a maze. If you're digging through a 300-page 10-K just to confirm how Differential Air Pressure technology drives AlterG sales, the task steals precious analysis hours. That’s why this page places Lifeward Ltd SEC filings explained simply at your fingertips. Stock Titan’s AI reads each document line-by-line, extracts the rehabilitation metrics that matter, and surfaces concise explanations that investors can act on immediately.
Whether you need the latest Lifeward Ltd quarterly earnings report 10-Q filing or an archived proxy, every submission hits this page seconds after EDGAR. Our platform pairs real-time feeds with AI-powered summaries so you can:
- Review a Lifeward Ltd annual report 10-K simplified to see segment revenue for ReWalk, AlterG, and MyoCycle
- Get a snapshot of Lifeward Ltd 8-K material events explained when FDA approvals or clinical study results are announced
- Dive into a Lifeward Ltd proxy statement executive compensation to benchmark R&D incentives
Each filing is accompanied by AI-generated key points, peer comparisons, and keyword search so you can move from document to decision in minutes.
Monitoring capital flows is just as easy. Track Lifeward Ltd insider trading Form 4 transactions, receive Lifeward Ltd Form 4 insider transactions real-time alerts, and analyze Lifeward Ltd executive stock transactions Form 4 before the market reacts. From Lifeward Ltd earnings report filing analysis to understanding Lifeward Ltd SEC documents with AI, Stock Titan turns raw disclosures into practical insights. No more sifting through multiple sources—our comprehensive coverage of every form, refreshed continuously, ensures you never miss a rehabilitation technology update that could move the stock.
Lifeward Ltd. (LFWD) is calling an Extraordinary General Meeting on January 6, 2026 to ask shareholders to approve several share capital changes. The main proposal would authorize the Board to implement a reverse share split of the ordinary shares at a ratio between 1-for-2 and 1-for-12, primarily to help Lifeward regain compliance with Nasdaq’s minimum $1.00 bid price rule after receiving a deficiency notice on August 5, 2025. As of November 17, 2025, Lifeward had 18,293,776 ordinary shares outstanding. A second proposal, contingent on the reverse split, would allow the Board to increase authorized share capital so the company could have up to 100,000,000 authorized shares post-split, preserving flexibility for future equity or debt-related financings. A third proposal would eliminate the par value of the ordinary shares, which the company says is a technical change intended to simplify capital structure without materially altering existing shareholder rights.
Lifeward Ltd. (LFWD) entered a secured financing, issuing a Secured Promissory Note to Oramed for $3.0 million. The loan is secured by a lien on cash, bears 15% annual interest, and matures on May 14, 2026. The note includes customary covenants and default provisions and may require a $500,000 termination fee under certain circumstances.
The note is convertible at $0.45 per ordinary share, with a 4.99% beneficial ownership limit and mandatory conversion under certain circumstances. Separately, the company furnished a press release announcing Q3 2025 results and held a conference call on November 14, 2025 at 8:30 a.m. E.S.T., with an archived webcast available for 30 days.
Lifeward Ltd. (LFWD) reported preliminary, unaudited Q3 results for the quarter ended September 30, 2025. The company estimates revenue of approximately $6.2 million and U.S. GAAP operating expenses of about $5.8–$5.9 million for the period.
Liquidity at quarter-end was limited, with cash and cash equivalents of approximately $2.0 million as of September 30, 2025. The company also stated its cash, cash equivalent and short‑term investment balance was approximately $2.0 million as of the same date.
Management prepared these figures and they are subject to customary quarter-end close procedures, which could change the amounts. The company’s independent auditor, EY, has not audited, reviewed, or compiled these results. Actual results will appear in the upcoming Form 10‑Q. The information was furnished under Item 2.02 and is not deemed filed under the Exchange Act.
Lifeward Ltd. insider sale to cover taxes following RSU vesting. Jeannine Lynch, VP of Market Access & Strategy and a director, reported the sale of 1,591 ordinary shares on 09/02/2025 at $0.64 per share to satisfy tax withholding tied to RSUs that vested on 08/31/2025. After the sale she beneficially owns 46,067 ordinary shares indirectly, and the transaction was executed under an automatic sell-to-cover arrangement mandated by her RSU grant agreement. The filing states the sale was not a discretionary trade by the reporting person.
The filing amends prior Form S-8 registration statements to reflect Lifeward Ltd.'s replacement of its ReWalk Robotics Ltd. 2014 Incentive Compensation Plan with the Lifeward Ltd. 2025 Incentive Compensation Plan. Shareholders approved the 2025 Plan effective August 1, 2025. There are 164,129 ordinary shares underlying outstanding awards under the 2014 Plan that may become issuable under the 2025 Plan. No additional shares are being registered by this amendment.
Lifeward Ltd. (LFWD) filed a post-effective amendment to prior Form S-8 registration statements to reflect the shareholder-approved Lifeward Ltd. 2025 Incentive Compensation Plan (the "2025 Plan") effective August 1, 2025. The amendment covers 164,129 Ordinary Shares underlying awards outstanding under the Registrant's 2014 Plan that, following the Effective Date, may become issuable under the 2025 Plan. No additional securities are being registered. The filing notes prior registrations totaling 916,676 Ordinary Shares (post reverse-splits) and describes that forfeited or cancelled shares under the 2014 Plan will be added back to the 2025 Plan. The document also incorporates the Company’s recent SEC reports by reference and includes standard indemnification and insurance disclosures under Israeli law.
Lifeward Ltd. filed a Post-Effective Amendment to prior Form S-8 registration statements to reflect shareholder approval of the Lifeward Ltd. 2025 Incentive Compensation Plan effective August 1, 2025. The amendment covers 164,129 Ordinary Shares underlying awards outstanding under the prior 2014 Plan that may become issuable under the 2025 Plan. No new shares are being registered. The filing notes prior registrations and two reverse share splits (1-for-25 and 1-for-7) and incorporates specified reports and plan exhibits by reference.
Lifeward Ltd. shareholders approved the Lifeward Ltd. 2025 Incentive Compensation Plan on August 1, 2025. Following the Effective Date, no new awards will be granted under the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan (the 2014 Plan) and 164,129 Ordinary Shares underlying existing awards under the 2014 Plan as of the Effective Date may be reallocated to the 2025 Plan if they become available. The filing amends prior S-8 registration statements to cover those 164,129 Outstanding Shares and notes prior registrations aggregated 916,676 Ordinary Shares (post reverse splits).
Lifeward Ltd. filed a Post-Effective Amendment on Form S-8 to transfer outstanding awards from its prior ReWalk Robotics Ltd. 2014 Incentive Compensation Plan into the Lifeward Ltd. 2025 Incentive Compensation Plan following shareholder approval on August 1, 2025. There are 164,129 ordinary shares underlying outstanding awards as of the Effective Date that will be covered to the extent they become issuable under the 2025 Plan. No additional securities are being registered. The filing notes prior reverse stock splits and incorporates by reference the company’s recent reports and governing documents.
Lifeward Ltd. filed a Form S-8 to register securities under its 2025 Incentive Compensation Plan for issuance to employees, executives and directors. The filing incorporates by reference the company’s recent annual and quarterly reports and numerous current reports, and lists exhibits including plan documents, award agreement forms for Israeli and non-Israeli participants, legal opinions, consents and a directors’ and officers’ insurance disclosure. The company describes indemnification, exculpation and insurance arrangements for office holders under Israeli law and confirms it has obtained D&O insurance and indemnification agreements to the fullest extent permitted. The filing is procedural and registers equity awards under the Plan.
FAQ
What is the current stock price of Lifeward (LFWD)?
What is the market cap of Lifeward (LFWD)?
